Objective
A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine is efficacious for the treatment of dementia in Parkinson’s disease (PD). We investigated the efficacy of rivastigmine for BPSD in patients with Parkinson’s disease dementia (PDD). Methods
Twenty-three patients in whom cognitive impairment occurred at least one year after a diagnosis of PD participated in this open-label trial. Cognitive, psychiatric, and motor symptoms were assessed before and after 24 weeks of treatment with rivastigmine using unstructured clinical assessments and rating scales including the Unified Parkinson’s Disease Rating Scale, Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory. Results
Age (± standard deviation) was 74.7 ± 5.9 years, average duration of PD was 3.5 ± 3.7 years, Hoehn and Yahr scores were 2.2 ± 0.8, and baseline MMSE scores were 19.1 ± 4.2. Improvements in global mental symptoms and neuropsychiatric symptoms were significant; among them, hallucination, depression and appetite changes improved. Caregiver distress significantly decreased, including distress resulting from hallucinations, depression, apathy, and appetite changes. Conclusions
Although controlled trials are required, the findings suggest that rivastigmine is useful for control of several neuropsychiatric symptoms and beneficial for caregiver distress in patients with PDD.
Citations
Citations to this article as recorded by
Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review Efthalia Angelopoulou, Evangelia Stanitsa, Claire Chrysanthi Karpodini, Anastasia Bougea, Dionysia Kontaxopoulou, Stella Fragkiadaki, Christos Koros, Vasiliki Epameinondas Georgakopoulou, George Fotakopoulos, Yiannis Koutedakis, Christina Piperi, Sokratis Medicina.2023; 59(8): 1454. CrossRef
Parkinsonism and dementia Christos Koros, Leonidas Stefanis, Nikolaos Scarmeas Journal of the Neurological Sciences.2022; 433: 120015. CrossRef
Current concepts in treating mild cognitive impairment in Parkinson's disease Jay S. Schneider, Sandhya Kortagere Neuropharmacology.2022; 203: 108880. CrossRef
Apathy in Parkinson’s Disease: Defining the Park Apathy Subtype Ségolène De Waele, Patrick Cras, David Crosiers Brain Sciences.2022; 12(7): 923. CrossRef
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis Łucja Justyna Walczak-Nowicka, Mariola Herbet International Journal of Molecular Sciences.2021; 22(17): 9290. CrossRef
Diagnosis and treatment of old-onset Parkinson's disease 久大 立花 Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics.2021; 58(3): 341. CrossRef
Neuropsychiatrische Störungen bei idiopathischem Parkinson-Syndrom Mario Paulig Nervenheilkunde.2021; 40(10): 752. CrossRef
Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson’s Disease Katie Pizzolato, David Thacker, Nicole Del Toro-Pagán, Abeer Hanna, Jacques Turgeon, Adriana Matos, Nishita Amin, Veronique Michaud Medicina.2021; 57(10): 1107. CrossRef
Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy Paolo Morana, Federico Mucci, Stefano Baroni, Alessandra Della Vecchia, Armando Piccinni, Benedetto Morana, Donatella Marazziti Clinical Case Reports.2020; 8(2): 254. CrossRef
Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems? Kathy Dujardin, Véronique Sgambato Frontiers in Neuroscience.2020;[Epub] CrossRef
Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson’s Disease, and Multiple Sclerosis: Diagnosis and Treatment Susan K. Conroy, Katherine B. Brownlowe, Thomas W. McAllister FOCUS.2020; 18(2): 150. CrossRef
Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice Claudia Lazcano-Ocampo, Yi Min Wan, Daniel J van Wamelen, Lucia Batzu, Iro Boura, Nataliya Titova, Valentina Leta, Mubasher Qamar, Pablo Martinez-Martin, K Ray Chaudhuri Expert Review of Neurotherapeutics.2020; 20(5): 477. CrossRef
Diagnosis, treatment and management of apathy in Parkinson’s disease: a scoping review Bria Mele, Shinia Van, Jayna Holroyd-Leduc, Zahinoor Ismail, Tamara Pringsheim, Zahra Goodarzi BMJ Open.2020; 10(9): e037632. CrossRef
Pharmacological treatment of apathy in Lewy body disorders: A systematic review Jennifer Liu, Christine A. Cooper, Daniel Weintraub, Nabila Dahodwala Parkinsonism & Related Disorders.2019; 60: 14. CrossRef
Current treatment of behavioral and cognitive symptoms of Parkinson's disease Irena Rektorova Parkinsonism & Related Disorders.2019; 59: 65. CrossRef
Approach to the management of psychosis in Parkinson’s disease Abhishek Lenka, Vasanthi Gomathinayagam, Laxman Bahroo Annals of Movement Disorders.2019; 2(3): 83. CrossRef
Risk factors for non-motor symptoms in Parkinson's disease Johan Marinus, Kangdi Zhu, Connie Marras, Dag Aarsland, Jacobus J van Hilten The Lancet Neurology.2018; 17(6): 559. CrossRef
The efficacy of pharmacological approaches to therapy of the apathy syndrome in dementia disorders (the review) A. S. Avedisova, A. B. Guekht, K. V. Zakharova, R. G. Akzhigitov Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2018; 118(4): 126. CrossRef
Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle Rita Moretti, Paola Caruso, Matteo Dal Ben Parkinson's Disease.2017; 2017: 1. CrossRef
Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature Philip E. Mosley, Rebecca Moodie, Nadeeka Dissanayaka Journal of Geriatric Psychiatry and Neurology.2017; 30(5): 235. CrossRef
Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment Stephane Thobois, Stephane Prange, Véronique Sgambato-Faure, Léon Tremblay, Emmanuel Broussolle Current Neurology and Neuroscience Reports.2017;[Epub] CrossRef
Parkinson's disease psychosis: presentation, diagnosis and management Ruth B Schneider, Julia Iourinets, Irene H Richard Neurodegenerative Disease Management.2017; 7(6): 365. CrossRef
Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson’s Disease Yunlong Zhang, Feng Tan, Pingyi Xu, Shaogang Qu Neural Plasticity.2016; 2016: 1. CrossRef
Neuropsychiatric Issues in Parkinson’s Disease Jeffrey W. Cooney, Mark Stacy Current Neurology and Neuroscience Reports.2016;[Epub] CrossRef
Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists Daniel Martinez-Ramirez, Michael S Okun, Michael S Jaffee Neurodegenerative Disease Management.2016; 6(4): 319. CrossRef
Pimavanserin for the treatment of Parkinson’s disease psychosis Ines Chendo, Joaquim J Ferreira Expert Opinion on Pharmacotherapy.2016; 17(15): 2115. CrossRef
Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments Fleur Harrison, Liesbeth Aerts, Henry Brodaty Current Psychiatry Reports.2016;[Epub] CrossRef
Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration Santiago Perez-Lloret, María Cecilia Peralta, Francisco J. Barrantes Expert Opinion on Pharmacotherapy.2016; 17(18): 2405. CrossRef